share_log

JP Morgan Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $10

Benzinga ·  Nov 13, 2023 11:03

JP Morgan analyst Eric Joseph maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral and lowers the price target from $11 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment